Pioneering digital diagnostics

We create health testing solutions for medical professionals that improve the rapid detection and characterisation of major diseases, enabling personalised treatment and better outcomes for patients.

EDX Medical specialises in Oncology, Cardiology, and Infectious Diseases.

National Cancer Institute Vb0gy3pwssm Unsplash

Products

EDX Medical Group plc is a UK-based listed company focused on the development of diagnostic tests that enable personalised treatment for cancer, cardiovascular and infectious diseases.

Our trusted diagnostic solutions combine outstanding biological and digital technologies. Our molecular biology laboratory in Cambridge, UK, leads our laboratory-based work. Health professionals, wherever they work, use our point-of-care devices to deliver critical patient test results.

Comprehensive Tumour Profiling (MI Profile)
Caris Life Sciences®
Caris MI Profile™ is a comprehensive tumour profiling platform designed to guide precision oncology. Through advanced whole exome sequencing (WES), whole transcriptome sequencing (WTS), and protein analysis, Caris MI Profile™…
Order Test Read More
cResponse™ Future of Cancer Therapy Selection
Curesponse
cResponse™ is an ex vivo functional platform that assess and predicts the effectiveness of single and multidrug chemotherapy, immunotherapy as well as innovative biological treatments on the tumour tissue.
Order Test Read More
Tumour Biopsy Molecular Profiling (MI Tumor Seek)
Caris Life Sciences®
MI Tumor Seek™ is a Next-Generation Sequencing (NGS)-based tumour profiling service that includes Whole Exome Sequencing (WES) analysis of DNA for mutations, copy number alterations*, insertions/deletions, genomic signatures (MSI, TMB*,…
Order Test Read More
Caris Assure®: Blood based tumour profiling
Caris Life Sciences®
Introduction Caris Assure® is blood based comprehensive molecular profiling designed for patients with previously diagnosed solid tumours when tissue biopsy is not feasible. It combines whole-exome sequencing (WES) of cell-free…
Order Test Read More
TC100 – Combined Blood Testing for Testicular Germ Cell Tumours
TC100 combines miR-371a-3p (M371) with classical serum markers to support diagnosis and follow-up of testicular germ cell tumours. Available via EDX Medical.
Read More
Prostate cancer ‘super test’
EDX Medical scientists working in Oxford and Cambridge have developed a new ‘super test’ for prostate cancer. The involves blood and urine samples which are analysed using the most comprehensive…
Read More
BC95 – Advanced Bowel Cancer Testing Service
BC95 is an advanced bowel cancer testing service combining complementary screening and genetic assessment tools to support clinical decision-making and referral pathways.
Read More
EarlyTect ® Stool DNA Test for Colorectal Cancer Screening
A stool-based molecular screening test that detects methylated SDC2 DNA associated with colorectal cancer. Supports non-invasive early detection and risk assessment.
Read More
Hereditary Cancer Testing – Multi-Gene Germline Panel
A comprehensive NGS test that identifies inherited variants in cancer-predisposition genes. It supports the diagnosis of hereditary cancer syndromes and informs risk assessment, surveillance, and family testing.
Read More
qFit – Quantitative Faecal Immunochemical Test
A stool-based screening test that detects human haemoglobin in faeces. Used to support colorectal cancer screening and identify patients who may require further investigation.
Read More
ARDP (Acute Respiratory Distress & Pneumonia) ICU test
EDX Medical is working in collaboration with Cambridge University, Addenbrooke’s Hospital, Cambridge, and the UK Health Security Agency (UKHSA) on the development of a new assay for early, definitive detection…
Read More
Available Soon
Multiple biomarker 5FU pharmacogenomic test
EDX Medical is developing, in collaboration with the University of Oxford, a new benchmark test for all patients receiving fluoropyrimidine-based chemotherapies.
Read More
Point of care multiplex sepsis test
EDX is launching a breakthrough, highly sensitive 20-minute bedside test that can detect the presence or absence of bacteria or viral infections and help guide the selection of the most…
Read More

Partners

EDX Medical Group has a partnership and distribution agreement with Caris Life Sciences (Caris), the US-based next-generation AI TechBio and precision medicine company, to distribute key Caris products and medical AI solutions exclusively in the UK. They include tumour biopsy molecular profiling (MI Profile); liquid (blood) biopsy molecular profiling (MI Tumour Seek) and minimum residual disease testing (MI Assure).
Read more →
EDX Medical Group has entered into a collaborative agreement with Thermo Fisher Scientific EMEA Ltd, a world leader in supplying life sciences solutions and services, to jointly develop and potentially commercialise a range of clinical-grade assays – including novel and innovative cancer diagnostic solutions.
Read more →
EDX Medical Group exclusively distributes the cResponse™ cancer assay in the UK, Sweden, Finland, Norway and Denmark. cResponse™ is a groundbreaking platform developed by Curesponse Ltd., a leading precision oncology company, that biologically assesses how an individual patient’s living tumour tissue responds to selected medicines, identifying the most effective treatment options.
Read more →

EDX Medical Group has a partnership and distribution agreement with Caris Life Sciences (Caris), the US-based next-generation AI TechBio and precision medicine company, to distribute key Caris products and medical AI solutions exclusively in the UK. They include tumour biopsy molecular profiling (MI Profile); liquid (blood) biopsy molecular profiling (MI Tumour Seek) and minimum residual disease testing (MI Assure).

EDX Medical Group has entered into a collaborative agreement with Thermo Fisher Scientific EMEA Ltd, a world leader in supplying life sciences solutions and services, to jointly develop and potentially commercialise a range of clinical-grade assays – including novel and innovative cancer diagnostic solutions.

EDX Medical Group exclusively distributes the cResponse™ cancer assay in the UK, Sweden, Finland, Norway and Denmark. cResponse™ is a groundbreaking platform developed by Curesponse Ltd., a leading precision oncology company, that biologically assesses how an individual patient’s living tumour tissue responds to selected medicines, identifying the most effective treatment options.

20m new cancer cases across the world in 2021

Early diagnosis, rapid adoption of personalised treatments and ongoing monitoring are already saving millions of lives, yet adoption remains surprisingly slow.

Heart disease is the leading cause of death in Western societies

Many risks of this and associated diseases such as diabetes can now be managed if risks are identified sufficiently early.

Neurodegeneration is the leading cause of loss of quality of life

The discovery of new biomarkers is accelerating the development of innovative medicines with disease-modifying potential.

Why digital diagnostics are important

There are more than 20million new cancer cases across the world each year and that number is rising. Heart disease is the leading cause of death in Western Societies. Tackling these and other widespread illnesses is the greatest of challenges. Early detection and management are proven to be the most effective means of saving and extending quality of life.

Our digitally-enabled products and services set new standards in risk assessment, personal diagnosis and enable better clinical decision-making.

EDX Medical provides healthcare professionals and organisations with reliable, high-performance tools and services for predicting and managing disease on a personalised basis.

Simple screening tests for use by professionals or individuals at ‘point-of-care’, home or workplace are backed up by definitive laboratory assays and genomic sequencing if required. These enable individuals and their professional carers to establish a fully personalised diagnosis to international standards.

Get in touch

To learn more about EDX Medical or arrange a meeting, please contact us using the form or email: info@edxmedical.co.uk

If you or your organisation are interested in partnering with EDX Medical visit our Working In Partnership page.

If you have any complaint regarding EDX Medical products or services, please contact Jake Hunter, Quality and Compliance Manager. E: jakeh@edxmedical.com

If you would like to provide feedback on EDX products and services, or wish to discuss any aspect of your testing process, please don’t hesitate to get in touch using our contact form: